Search

Your search keyword '"Comino-Méndez, Iñaki"' showing total 153 results

Search Constraints

Start Over You searched for: Author "Comino-Méndez, Iñaki" Remove constraint Author: "Comino-Méndez, Iñaki"
153 results on '"Comino-Méndez, Iñaki"'

Search Results

2. Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients

3. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

4. Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients

6. Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates

7. Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients

8. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

9. Gain-of-function mutations in DNMT3A in patients with paraganglioma

10. Abstract 6610: Increasing blood volumes to detect minimal residual disease in neoadjuvant-treated early breast cancer patients

11. Supplementary Figure S1 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

12. supplemental legend from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

13. Supplementary methods and Figure Legends from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

14. Supplemental Figure 1 from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

15. Supplementary Table S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

16. Supplementary Figure S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

17. Supplementary Figure 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

18. Supplementary Figure Legends from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

19. Supplementary Table 1 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

20. Supplementary Table S1 from Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

21. Supplementary Figure 1 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

22. Supplementary Figures 1 - 3 from MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma

23. Supplementary Table 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

24. Supplementary Figure Legend from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy

25. Supplemental Table 2 from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

26. Supplemental Table 1 from DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

27. Data from Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

28. Supplementary Table 3 from Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

29. Supplementary Table 2 from Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

30. Supplementary Table 1 from Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

31. Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis

32. Functional and in silico assessment of MAX variants of unknown significance

33. Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene

35. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients

36. Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.

37. The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer

38. Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment

39. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis

41. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

43. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

44. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer–Predisposing Mutations in Pheochromocytomas and Paragangliomas

45. The identification of new familial pheochromocytoma/paraganglioma genes using whole exome sequencing

46. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers

47. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers

48. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers

49. VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma

50. Gain-of-function mutations in DNMT3Ain patients with paraganglioma

Catalog

Books, media, physical & digital resources